DERM
Price
$7.56
Change
+$0.08 (+1.07%)
Updated
Apr 24 closing price
Capitalization
73.35M
18 days until earnings call
DRMA
Price
$0.75
Change
-$0.04 (-5.06%)
Updated
Apr 24 closing price
Capitalization
4.07M
Ad is loading...

DERM vs DRMA

Header iconDERM vs DRMA Comparison
Open Charts DERM vs DRMABanner chart's image
Journey Medical
Price$7.56
Change+$0.08 (+1.07%)
Volume$113.37K
Capitalization73.35M
Dermata Therapeutics
Price$0.75
Change-$0.04 (-5.06%)
Volume$197.48K
Capitalization4.07M
DERM vs DRMA Comparison Chart
Loading...
DERM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DRMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DERM vs. DRMA commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DERM is a StrongBuy and DRMA is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (DERM: $7.56 vs. DRMA: $0.75)
Brand notoriety: DERM: Notable vs. DRMA: Not notable
DERM represents the Pharmaceuticals: Other, while DRMA is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: DERM: 142% vs. DRMA: 10%
Market capitalization -- DERM: $73.35M vs. DRMA: $4.07M
DERM [@Pharmaceuticals: Other] is valued at $73.35M. DRMA’s [@Biotechnology] market capitalization is $4.07M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.67B. The average market capitalization across the [@Biotechnology] industry is $2.16B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DERM’s FA Score shows that 0 FA rating(s) are green whileDRMA’s FA Score has 0 green FA rating(s).

  • DERM’s FA Score: 0 green, 5 red.
  • DRMA’s FA Score: 0 green, 5 red.
According to our system of comparison, DERM is a better buy in the long-term than DRMA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DERM’s TA Score shows that 5 TA indicator(s) are bullish while DRMA’s TA Score has 5 bullish TA indicator(s).

  • DERM’s TA Score: 5 bullish, 4 bearish.
  • DRMA’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, DERM is a better buy in the short-term than DRMA.

Price Growth

DERM (@Pharmaceuticals: Other) experienced а +20.96% price change this week, while DRMA (@Biotechnology) price change was +2.88% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +4.30%. For the same industry, the average monthly price growth was -2.30%, and the average quarterly price growth was -8.27%.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.06%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -11.62%.

Reported Earning Dates

DERM is expected to report earnings on Aug 12, 2025.

DRMA is expected to report earnings on Mar 17, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+4.30% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

@Biotechnology (+8.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DERM($73.4M) has a higher market cap than DRMA($4.07M). DERM YTD gains are higher at: 93.350 vs. DRMA (-44.444). DERM has higher annual earnings (EBITDA): -5.69M vs. DRMA (-11.53M). DERM has more cash in the bank: 24.7M vs. DRMA (6.14M). DERM has less debt than DRMA: DERM (131K) vs DRMA (175K). DERM has higher revenues than DRMA: DERM (79.9M) vs DRMA (0).
DERMDRMADERM / DRMA
Capitalization73.4M4.07M1,802%
EBITDA-5.69M-11.53M49%
Gain YTD93.350-44.444-210%
P/E RatioN/AN/A-
Revenue79.9M0-
Total Cash24.7M6.14M402%
Total Debt131K175K75%
FUNDAMENTALS RATINGS
DERM: Fundamental Ratings
DERM
OUTLOOK RATING
1..100
28
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
35
P/E GROWTH RATING
1..100
40
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
DERMDRMA
RSI
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 15 days ago
87%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 4 days ago
89%
View a ticker or compare two or three
Ad is loading...
DERM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DRMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GEO29.971.64
+5.79%
GEO Group (The)
SOFI12.310.57
+4.86%
SoFi Technologies
ORCL137.516.11
+4.65%
Oracle Corp
CIX26.950.48
+1.81%
Comp X International
WHWK1.51-0.03
-1.95%
Whitehawk Therapeutics Inc

DERM and

Correlation & Price change

A.I.dvisor tells us that DERM and CRDL have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DERM and CRDL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DERM
1D Price
Change %
DERM100%
+1.07%
CRDL - DERM
27%
Poorly correlated
-0.93%
CHRS - DERM
27%
Poorly correlated
-9.01%
AQST - DERM
25%
Poorly correlated
+1.06%
VXRT - DERM
24%
Poorly correlated
+4.74%
DRMA - DERM
22%
Poorly correlated
-5.35%
More

DRMA and

Correlation & Price change

A.I.dvisor indicates that over the last year, DRMA has been loosely correlated with IRON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if DRMA jumps, then IRON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DRMA
1D Price
Change %
DRMA100%
-5.35%
IRON - DRMA
43%
Loosely correlated
+2.26%
KANT - DRMA
28%
Poorly correlated
+38.53%
KRRO - DRMA
28%
Poorly correlated
-2.90%
AVXL - DRMA
27%
Poorly correlated
+1.50%
KALA - DRMA
26%
Poorly correlated
+5.77%
More